For people with Type-2 Diabetes, Glenmark has introduced Sitagliptin in India
According to a regulatory filing by Glenmark, the company has made eight distinct sitagliptin-based medication combinations available.
admin
On Thursday, Glenmark Pharmaceuticals Ltd. introduced the SITAZIT brand and its variations in India along with sitagliptin and its fixed dose combinations (FDCs) designed for adults with type-2 diabetes.
According to a regulatory filing by Glenmark, the company has made eight distinct sitagliptin-based medication combinations available.
SITAZIT (sitagliptin) will be offered in 50 mg and 100 mg variants; SITAZIT M will have sitagliptin (50 mg) + metformin (500 mg/1000 mg); SITAZIT M ER will have sitagliptin (100 mg) + metformin SR (500 mg/1000 mg), the company said. The medications will be sold under the brand names SITAZIT, SITAZIT- M, SITAZIT- M
SITAZIT (sitagliptin) will be offered in 50 mg and 100 mg dosages; SITAZIT M will contain 50 mg of sitagliptin with 500 mg or 1000 mg of metformin.
Additionally, it was stated that SITAZIT D is a novel combination that comes in two forms: SITAZIT D 100/10, which contains sitagliptin (100 mg) and dapagliflozin (10 mg), and SITAZIT D 50/5, which contains sitagliptin (50 mg) and dapagliflozin (15 mg) (5 mg). According to the firm, people with chronic conditions like type-2 diabetes must take numerous anti-diabetic medications for extended periods of time.
In addition, patients in India are responsible for paying for their own medications, making drug costs a significant factor in treatment compliance. In India, the cost of Glenmark's sitagliptin and its FDCs is said to be about one-third that of its originator brand.
The Januvia brand of sitagliptin phosphate 10 mg tablets from MSD Pharmaceuticals retails for about Rs 300 for a strip of seven tablets. According to Glenmark, SITAZIT and its derivatives will "play a crucial role in increasing sitagliptin accessible to type-2 diabetic patients."
Sitagliptin and its fixed-dose combinations have a minimal risk of hypoglycemia, protect beta cells, have positive effects on the heart and kidneys, and are safe for elderly individuals and those with kidney or liver disease. According to the firm, patients will be able to manage their glucose level more effectively and exhibit improved compliance.
